Lazard Asset Management
PHAT icon

Lazard Asset Management’s Phathom Pharmaceuticals PHAT Stock Holding History

Lazard Asset Management’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$159K Hold
14,671
– – ﹤0.01% 1706
2026
Q1 		$163K Buy
+14,671
New +$185K ﹤0.01% 1665

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Lazard Asset Management's PHAT Position: Q2 2026 in Review

Lazard Asset Management held its Phathom Pharmaceuticals (PHAT) position steady in Q2 2026 at 14,671 shares worth $159K. The position accounts for ﹤0.01% of the portfolio, ranked #1706.

Lazard Asset Management first reported a position in PHAT in Q1 2026 and has held it in 2 quarters since. The position peaked at $163K in Q1 2026. 162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Lazard Asset Management held 14,671 shares of Phathom Pharmaceuticals worth $159K as of Q2 2026.
  • Lazard Asset Management left its Phathom Pharmaceuticals share count unchanged in Q2 2026.
  • Phathom Pharmaceuticals made up ﹤0.01% of Lazard Asset Management's portfolio in Q2 2026, its #1706 holding.
  • Lazard Asset Management first reported a position in Phathom Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Lazard Asset Management's Phathom Pharmaceuticals position peaked at $163K in Q1 2026.
  • 162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.